RxDoctor Payments Data

Shelley Drew, DO

Family Medicine · Walker, MINPI 1679536726

Payments from drug & device makers

$12,309in general payments, 2019–2025

Across 747 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$1K
  • Pfizer$926
  • plus $4K from 44 others

What the payments were for

  • Travel & lodging$50%
  • Food & beverage$12,285100%
  • Education$200%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,309 in reported general payments places this provider in the 95th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$31,653
Medicare patients
57
Services billed
553

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol86$83,305
MounjaroTirzepatide47$66,615
Trelegy ElliptaFluticasone/Umeclidin/Vilanter72$55,515
JardianceEmpagliflozin34$41,309
TrulicityDulaglutide23$32,977
JanuviaSitagliptin Phosphate22$28,573
OzempicSemaglutide16$21,198
MyrbetriqMirabegron27$20,506
LinzessLinaclotide13$13,685
Repatha SureclickEvolocumab19$9,746
Spiriva RespimatTiotropium Bromide13$6,609
Atorvastatin Calcium286$5,710
Duloxetine Hcl83$2,830
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide46$2,793
Fluticasone-SalmeterolFluticasone Propion/Salmeterol14$2,773

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,379$99,59270 claims
AstraZenecaFarxiga$1,668$83,30586 claims
GSKTrelegy Ellipta$604$55,51572 claims
Boehringer IngelheimJardiance, Spiriva Respimat$1,011$47,91847 claims
MerckJanuvia$397$28,57322 claims
Novo NordiskOzempic$1,270$21,19816 claims
Astellas Pharma US IncMyrbetriq$230$20,50627 claims
AbbVieLinzess$1,719$13,68513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Walker

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →